Horizon製藥公共 HZNP 深 滬
已收盤 10-06 16:00:00 美东时间
116.30
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 116.30
- 總市值 266.33亿
- 52周最高 116.38
- 市盈率 靜 52.46
- 換手率 0.00%
- 52周最低 60.03
- 委 比 0.00%
- 總股本 2.29亿
- 歷史最高 120.535
- 量 比 0
- 振 幅 0.00%
- 歷史最低 1.965
- 每 手 1
- 風險率 0.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galapagos appoints Aaron Cox as CFO
Galapagos (OTCPK:GLPGF) has announced the appointment of Aaron Cox as CFO, effective July 7, 2025. Cox succeeds Thad Huston, who will remain with the company through July 31, 2025, to ensure a smooth ...
06-23 14:35
2024 年全球大型药企薪酬最高十位 CEO
（转自：抗体圈） 尽管在 Fierce 的 2024 年制药公司首席执行官薪酬排行榜上出现了许多熟悉的名字，但多位高管的排名发生了巨大变化，而第一名被一位黑马候...
06-18 11:23
IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New Engla...
06-02 20:04
Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease
The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the country’s medicine indicated specifically for adults with moderate to severe th...
05-08 02:16
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the fi...
05-02 04:01
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy THOUSAND OAKS, Calif., April 11, 20...
04-11 21:00
医药生物行业专题：海外制药企业2024Q4&全年业绩回顾
创新品种放量依然是增长的主要驱动力。2024年，礼来及诺和诺德在GLP-1类药物驱动下，收入端分别+32%/+25%；阿斯利康在奥希替尼、达格列净等品种驱动下收...
03-07 20:14
翰森制药(03692)等药企联合申报 抗CD19单抗新适应症申报上市
3月4日，中国国家药监局药品审评中心官网公示，由Horizon Therapeutics、阿斯利康(AZN.US)和翰森制药(03692)共同申报伊奈利珠单抗注...
03-04 10:08
BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
SAN RAFAEL, Calif., Feb. 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has appointed Timothy P. Walbert, former chairman, president an...
02-25 05:05
四季度，高瓴资本买了哪些医药股？
转自：新康界 作为华人资本圈的顶级投资机构，高瓴资本的持仓一直是华人美股投资界的风向标，近日，高瓴资本2024年四季度持仓披露，依然以互联网与生物医药为主，通常...
02-24 15:47
